Transamerica Financial Advisors’s Maravai LifeSciences MRVI Stock Holding History

Transamerica Financial Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$149	Hold	24	–	–	﹤0.01%	1934
2026 Q1	$67	Hold	24	–	–	﹤0.01%	1814
2025 Q4	$78	Hold	24	–	–	﹤0.01%	1710
2025 Q3	$69	Buy	+24	New	+$61	﹤0.01%	1552

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Transamerica Financial Advisors's MRVI Position: Q2 2026 in Review

Transamerica Financial Advisors held its Maravai LifeSciences (MRVI) position steady in Q2 2026 at 24 shares worth $149. The position accounts for ﹤0.01% of the portfolio, ranked #1934.

Transamerica Financial Advisors first reported a position in MRVI in Q3 2025 and has held it in 4 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Transamerica Financial Advisors held 24 shares of Maravai LifeSciences worth $149 as of Q2 2026.
Transamerica Financial Advisors left its Maravai LifeSciences share count unchanged in Q2 2026.
Maravai LifeSciences made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1934 holding.
Transamerica Financial Advisors first reported a position in Maravai LifeSciences in Q3 2025 and has held it in 4 quarters since.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.